Shares of Lantheus Holdings were added after the company received FDA approval of its key product TruVu.
We used recent weakness as an opportunity to initiate a position in Talen Energy, an independent power producer whose portfolio includes the Susquehanna nuclear plant and other dispatchable generation assets.
We exited Cactus as we lost confidence that its major growth lever, expansion into the Middle East, would play out in 2026 amid the escalating conflict in the region.
We exited our position in Littelfuse, Inc. following significant price appreciation to fund other ideas in the portfolio.
